Sana Biotechnology Inc
SANA
Company Profile
Business description
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
Contact
188 East Blaine Street
Suite 350
SeattleWA98102
USAT: +1 206 701-7914
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
142
Stocks News & Analysis
stocks
The World Cup stock you’ve never heard of
This ASX stock is kicking goals at the FIFA World Cup.
stocks
Chart of the Week: Can WiseTech shares finally bounce back?
Market concerns over governance and AI fears have left shares trading well below the fair value.
stocks
Steep downgrade for wide moat share
Regulatory pressures squeeze growth outlook for wide moat ASX share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.30 | 38.70 | 0.43% |
| CAC 40 | 8,252.66 | 183.58 | -2.18% |
| DAX 40 | 24,897.45 | 567.80 | -2.23% |
| Dow JONES (US) | 52,348.39 | 576.76 | -1.09% |
| FTSE 100 | 10,489.04 | 176.84 | -1.66% |
| HKSE | 24,199.46 | 702.57 | 2.99% |
| NASDAQ | 25,870.65 | 51.96 | 0.20% |
| Nikkei 225 | 66,819.05 | 1,437.91 | -2.11% |
| NZX 50 Index | 13,666.03 | 0.85 | 0.01% |
| S&P 500 | 7,482.71 | 21.14 | -0.28% |
| S&P/ASX 200 | 8,785.10 | 47.50 | 0.54% |
| SSE Composite Index | 3,970.88 | 19.36 | -0.49% |